First Wave BioPharma, Inc. (FWBI)

NASDAQ: FWBI · IEX Real-Time Price · USD
3.950
-0.020 (-0.50%)
At close: Mar 27, 2024, 4:00 PM
3.900
-0.050 (-1.27%)
After-hours: Mar 27, 2024, 7:38 PM EDT

Company Description

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases.

Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties.

The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis.

It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis.

The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021.

First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

First Wave BioPharma, Inc.
First Wave BioPharma logo
Country United States
IPO Date Oct 11, 2016
Industry Biotechnology
Sector Healthcare
Employees 10
CEO James R. Sapirstein M.B.A., R.Ph.

Contact Details

Address:
777 Yamato Road, Suite 502
Boca Raton, Florida 33431
United States
Phone 561-589-7020
Website firstwavebio.com

Stock Details

Ticker Symbol FWBI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001604191
CUSIP Number 33749P101
ISIN Number US33749P4081
Employer ID 46-4993860
SIC Code 2834

Key Executives

Name Position
James R. Sapirstein M.B.A., R.Ph. Chief Executive Officer and Chairman
Sarah Romano CPA Chief Financial Officer
Dr. Jack A. Syage Ph.D. President, Chief Operating Officer and Director
Amy Chandler-Skerkis Vice President of Regulatory Affairs, QA and Compliance
Martin Krusin M.B.A. Senior Vice President of Corporate Development

Latest SEC Filings

Date Type Title
Mar 22, 2024 8-K Current Report
Mar 18, 2024 8-K Current Report
Mar 18, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 14, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 14, 2024 8-K Current Report
Mar 5, 2024 8-K Current Report
Mar 4, 2024 424B5 Filing
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 18, 2024 424B3 Prospectus
Jan 17, 2024 EFFECT Notice of Effectiveness